文献速递新药、器械与细胞基因治疗研发临床试验与 GCP

bidridistrogene xeboparvovec基因治疗肢带型肌营养不良2E/R4型:1/2期试验结果

Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results.
PubMed 文献 · Nat Med · 2024-01-04

这项首次人体、开放标签、非随机1/2期试验评估了基于腺相关病毒的bidridistrogene xeboparvovec基因治疗在4-15岁SGCB双等位基因突变患者中的安全性和疗效。6例患者接受单次静脉输注,第60天骨骼肌SGCB表达较基线明显增加,Cohort 1平均为正常表达的36.2%,Cohort 2为62.1%。最常见治疗相关不良事件为呕吐和γ-谷氨酰转移酶升高,严重不良事件经标准治疗缓解;探索性分析显示North Star评估的运动改善维持至第2年。

要点

  • 第60天SGCB表达均值:Cohort 1为正常表达的36.2%(s.d. 2.7%),Cohort 2为62.1%(s.d. 8.7%)。
  • 最常见治疗相关不良事件为呕吐(6例中4例)和γ-谷氨酰转移酶升高(6例中3例)。
  • 探索性分析显示North Star评估的运动改善维持至第2年,需进一步研究确认长期安全性和疗效。

核心结论

  • bidridistrogene xeboparvovec的2年安全性和疗效支持推进临床开发。
  • 需进一步研究确认该基因治疗的长期安全性和疗效。

研究设计与样本

  • 首次人体、开放标签、非随机1/2期试验,评估bidridistrogene xeboparvovec的安全性和疗效。
  • 纳入4-15岁、两个等位基因均确认SGCB突变的患者,接受单次静脉输注1.85 × 10^13 vector genome copies kg^-1(Cohort 1,n=3)或7.41 × 10^13 vector gene copies kg^-1(Cohort 2,n=3)。
  • 主要终点为安全性,次要终点为第60天骨骼肌SGCB表达较基线的变化;报告第2年中期结果,试验仍在进行中。

主要发现

  • 最常见治疗相关不良事件为呕吐(6例中4例)和γ-谷氨酰转移酶升高(6例中3例)。
  • 严重不良事件经标准治疗缓解。
  • 第60天SGCB表达均值(s.d.):Cohort 1为正常表达的36.2%(2.7%),Cohort 2为62.1%(8.7%)。
  • 事后探索性分析显示,使用North Star Assessment for Limb-girdle Type Muscular Dystrophies评估的初步运动改善维持至第2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步研究确认该基因治疗的长期安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limb-girdle muscular dystrophy 2E/R4 is caused by mutations in the β-sarcoglycan (SGCB) gene, leading to SGCB deficiency and consequent muscle loss. We developed a gene therapy approach based on functional replacement of the deficient SCB protein. Here we report interim results from a first-in-human, open-label, nonrandomized, phase 1/2 trial evaluating the safety and efficacy of bidridistrogene xeboparvovec, an adeno-associated virus-based gene therapy containing a codon-optimized, full-length human SGCB transgene. Patients aged 4-15 years with confirmed SGCB mutations at both alleles received one intravenous infusion of either 1.85 × 1013 vector genome copies kg-1 (Cohort 1, n = 3) or 7.41 × 1013 vector gene copies kg-1 (Cohort 2, n = 3). Primary endpoint was safety, and secondary endpoint was change in SGCB expression in skeletal muscle from baseline to Day 60. We report interim Year 2 results (trial ongoing). The most frequent treatment-related adverse events were vomiting (four of six patients) and gamma-glutamyl transferase increase (three of six patients). Serious adverse events resolved with standard therapies. Robust SGCB expression was observed: Day 60 mean (s.d.) percentage of normal expression 36.2% (2.7%) in Cohort 1 and 62.1% (8.7%) in Cohort 2. Post hoc exploratory analysis showed preliminary motor improvements using the North Star Assessment for Limb-girdle Type Muscular Dystrophies maintained through Year 2. The 2-year safety and efficacy of bidridistrogene xeboparvovec support clinical development advancement. Further studies are necessary to confirm the long-term safety and efficacy of this gene therapy. ClinicalTrials.gov registration: NCT03652259 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mendell JR, Pozsgai ER, Lewis S, et al. Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results. Nat Med. 2024. PMID: 38177855. doi:10.1038/s41591-023-02730-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。